Aspen Pharmacare investors eye CEO’s $1.2 million pay after weak results
Aspen investors head into December AGM after years of weak earnings and share losses, ready to question whether CEO pay still makes sense.
Aspen Pharmacare
South African executive Gus Attridge loses $10 million as Aspen shares fall
South African pharma leader Gus Attridge sees a $10.7 million drop in his Aspen stake as the drugmaker’s shares slide and investor concerns deepen in 2025.
Aspen’s market slide wipes $20 million off Stephen Saad’s stake
Stephen Saad’s Aspen Pharmacare stake drops by $20 million as the company’s stock slips 6 percent on the Johannesburg Stock Exchange (JSE).
South African pharma tycoon Stephen Saad’s Aspen stake tops $340 million
Aspen Pharmacare shares edge higher, boosting CEO Stephen Saad’s holdings above $340 million despite the stock’s 37% year-to-date decline.
South Africa’s Stephen Saad expects $50 million sales from Aspen’s weight loss drug
South African pharma tycoon Stephen Saad says Aspen’s weight loss drug could reach $50 million in sales within two years.
South African pharma tycoon Gus Attridge loses $15.8 million on Aspen stake
Aspen co-founder Gus Attridge loses $15.8 million in three weeks as drug stocks fall, cutting Aspen’s value below $2.6 billion.
South African pharma tycoon Stephen Saad loses $44 million from Aspen stake
Aspen Pharmacare shares slide 33 percent, cutting Stephen Saad’s stake by $44 million amid global pharma pressures.
South African pharma mogul Stephen Saad’s Aspen stake sinks under $360 million
Aspen Pharmacare CEO Stephen Saad loses $32 million in 13 days as stock slumps; his stake now worth under $360 million amid JSE sell-off.
South African pharma tycoon Stephen Saad’s Aspen stake falls below $400 million
Stephen Saad’s stake slips below $400 million as Aspen shares fall 5.2% dragging market cap under $3 billion.
South African tycoon Stephen Saad's Aspen opens regional headquarters in Saudi Arabia
Aspen’s investment comes amid a broader push to localize manufacturing, enhance drug supply chains, and develop regional talent.
Stephen Saad’s Aspen stake drops $21 million in value
This mirrors wider investor caution amid challenges facing the global pharmaceutical sector and instability in emerging markets.
Stephen Saad raises Aspen stake by $5.6 million amid stock slump
Stephen Saad invests $5.6 million more in Aspen amid its biggest stock slump in two decades, signaling confidence in the company’s long-term outlook.
Stephen Saad loses $130 million as Aspen shares fall amid contract dispute
This follows a $148.7 million contract dispute tied to mRNA technology.
Stephen Saad’s Aspen faces $148.7 million contract dispute
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.
Gus Attridge gains over $18 million as Aspen shares rebound
This follows a strong recovery in Aspen's share price on the Johannesburg Stock Exchange (JSE).
Stephen Saad’s stake in Aspen slips below $450 million
South African pharma tycoon Stephen Saad’s stake in Aspen Pharmacare drops to $434.35 million, losing $62.85 million in 15 days.